AR042398A1 - Compuestos de pirazol utiles como inhibidores de proteinquinasa - Google Patents

Compuestos de pirazol utiles como inhibidores de proteinquinasa

Info

Publication number
AR042398A1
AR042398A1 ARP010105961A ARP010105961A AR042398A1 AR 042398 A1 AR042398 A1 AR 042398A1 AR P010105961 A ARP010105961 A AR P010105961A AR P010105961 A ARP010105961 A AR P010105961A AR 042398 A1 AR042398 A1 AR 042398A1
Authority
AR
Argentina
Prior art keywords
ring
so2n
con
nitrogen
substituted
Prior art date
Application number
ARP010105961A
Other languages
English (en)
Spanish (es)
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR042398A1 publication Critical patent/AR042398A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
ARP010105961A 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa AR042398A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25788700P 2000-12-21 2000-12-21
US28694901P 2001-04-27 2001-04-27

Publications (1)

Publication Number Publication Date
AR042398A1 true AR042398A1 (es) 2005-06-22

Family

ID=26946273

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP010105961A AR042398A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa
ARP010105960A AR042397A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa
ARP010105963A AR040925A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa
ARP010105962A AR042169A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa

Family Applications After (3)

Application Number Title Priority Date Filing Date
ARP010105960A AR042397A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa
ARP010105963A AR040925A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa
ARP010105962A AR042169A1 (es) 2000-12-21 2001-12-20 Compuestos de pirazol utiles como inhibidores de proteinquinasa

Country Status (27)

Country Link
US (16) US7625913B2 (enExample)
EP (10) EP1702920B1 (enExample)
JP (19) JP2004518743A (enExample)
KR (8) KR100843114B1 (enExample)
CN (6) CN1486310A (enExample)
AP (2) AP1588A (enExample)
AR (4) AR042398A1 (enExample)
AT (9) ATE327989T1 (enExample)
AU (7) AU2002255452B2 (enExample)
BR (2) BR0116493A (enExample)
CA (8) CA2432131C (enExample)
CY (1) CY1106297T1 (enExample)
DE (8) DE60119776T2 (enExample)
DK (3) DK1353916T3 (enExample)
ES (7) ES2375491T3 (enExample)
HU (5) HUP0400639A3 (enExample)
IL (8) IL156369A0 (enExample)
MX (8) MXPA03005610A (enExample)
MY (1) MY140377A (enExample)
NO (5) NO328537B1 (enExample)
NZ (8) NZ526471A (enExample)
PL (2) PL210414B1 (enExample)
PT (3) PT1355905E (enExample)
RU (1) RU2355688C2 (enExample)
SI (2) SI1355905T1 (enExample)
TW (2) TWI290551B (enExample)
WO (8) WO2002062789A1 (enExample)

Families Citing this family (379)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982260B1 (en) 1999-11-22 2006-01-03 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001296871A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2307667T3 (es) * 2000-12-05 2008-12-01 Vertex Pharmaceuticals Incorporated Inhibidires de quinasas terminales c-jun(jnk) y otras proteinas quinasas.
HUP0400639A3 (en) * 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
MXPA03008658A (es) * 2001-03-23 2005-04-11 Bayer Ag Inhibidores de rho-cinasa.
ATE400274T1 (de) 2001-04-10 2008-07-15 Merck & Co Inc Hemmstoffe der akt aktivitÀt
US7105667B2 (en) * 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
US7138404B2 (en) * 2001-05-23 2006-11-21 Hoffmann-La Roche Inc. 4-aminopyrimidine derivatives
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
WO2003026666A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
DE60238999D1 (de) * 2001-09-26 2011-03-03 Pfizer Italia Srl Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2002361846A1 (en) * 2001-12-21 2003-07-15 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
EP1465610B1 (en) * 2002-01-10 2008-12-31 F. Hoffmann-La Roche Ag Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP4656838B2 (ja) * 2002-02-06 2011-03-23 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ§ïœ“ïœ‹âˆ’ïŒ“ăźé˜»ćźłć‰€ăšă—ăŠæœ‰ç”šăȘヘテロケăƒȘăƒŒăƒ«ćŒ–ćˆç‰©
WO2003078426A1 (en) * 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazine as inhibitors of protein kinases
EP1485100B1 (en) * 2002-03-15 2010-05-05 Vertex Pharmaceuticals Incorporated Azinylaminoazoles as inhibitors of protein kinases
EP1485380B1 (en) 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines as inhibitors of protein kinases
WO2003086394A1 (en) 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
WO2003104230A1 (ja) 2002-06-07 2003-12-18 ć”ć’Œé†±é…”ć·„æ„­æ ȘćŒäŒšç€Ÿ äșŒç’°æ€§ăƒ”ăƒȘミゾンèȘ˜ć°Žäœ“
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
AU2003261204A1 (en) * 2002-07-23 2004-02-09 Smithkline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
CN103169708B (zh) 2002-07-29 2018-02-02 é‡Œæ Œć°”èŻć“è‚Ąä»œæœ‰é™ć…Źćž 甹2,4â€‘ć˜§ć•¶äșŒèƒșćŒ–ćˆç‰©æČ»ç–—æˆ–è€…éą„é˜Čè‡Șäœ“ć…ç–«æ€§ç–Ÿç—…çš„æ–čæł•
PL374967A1 (en) 2002-08-02 2005-11-14 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
SI1532145T1 (sl) * 2002-08-02 2007-02-28 Vertex Pharma Pirazolni sestavki, koristni kot inhibitorji GSK-3
AU2003278249B8 (en) 2002-09-05 2010-11-18 Aventis Pharma S.A. Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
FR2844267B1 (fr) * 2002-09-05 2008-02-15 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
AU2003255482A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
KR101122782B1 (ko) * 2002-10-04 2012-04-12 프띌나 ë°”ìŽì˜€í…ŒíŹë†€ëĄœì§€ 멬믾티드 신êČœ 활성 í™”í•©ëŹŒ
KR100490893B1 (ko) * 2002-10-11 2005-05-23 (ìŁŒ) ëč„엔씚바읎였팜 2-ë©”í†Ąì‹œ-1,3,5-íŠžëŠŹì•„ì§„ 유도ìČŽ, ê·ž ì œìĄ°ë°©ëȕ 및 읎넌 포핹하는 í•­ë°”ìŽëŸŹìŠ€ìš© 앜학적 ìĄ°ì„±ëŹŒ
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
US7309701B2 (en) 2002-11-19 2007-12-18 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
US7462613B2 (en) 2002-11-19 2008-12-09 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
PT2316831E (pt) 2002-11-21 2013-06-06 Novartis Ag 2-(morfolin-4-il)pirimidinas como inibidores da fosfatidilinositol (pi) quinase e a sua utilização no tratamento do cancro
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
EP1644338A1 (en) * 2003-04-01 2006-04-12 Aponetics AG 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
EP1635837B1 (en) * 2003-06-02 2008-07-16 AstraZeneca AB (3-((quinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
WO2004112719A2 (en) * 2003-06-19 2004-12-29 Smithkline Beecham Corporation Chemical compounds
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
GB0315966D0 (en) * 2003-07-08 2003-08-13 Cyclacel Ltd Compounds
CA2532965C (en) 2003-07-22 2013-05-14 Astex Therapeutics Limited 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
WO2005012262A1 (en) * 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US7417726B2 (en) * 2003-09-19 2008-08-26 Applied Biosystems Inc. Normalization of data using controls
US20050221357A1 (en) * 2003-09-19 2005-10-06 Mark Shannon Normalization of gene expression data
US20060024690A1 (en) * 2003-09-19 2006-02-02 Kao H P Normalization of data using controls
WO2005030131A2 (en) * 2003-09-23 2005-04-07 Replidyne, Inc Bis-quinazoline compounds for the treatment of bacterial infections
CA2542522A1 (en) 2003-10-17 2005-05-06 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
CA2548172A1 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
RU2006124559A (ru) * 2003-12-09 2008-01-20 ВДртДĐșс Đ€Đ°Ń€ĐŒĐ°ŃŃŒŃŽŃ‚ĐžĐșалз Đ˜ĐœĐșĐŸŃ€ĐżĐŸŃ€Đ”ĐčтДЎ (Us) ĐŸŃ€ĐŸĐžĐ·ĐČĐŸĐŽĐœŃ‹Đ” ĐœĐ°Ń„Ń‚ĐžŃ€ĐžĐŽĐžĐœĐ° Đž ĐżŃ€ĐžĐŒĐ”ĐœĐ”ĐœĐžĐ” уĐșĐ°Đ·Đ°ĐœĐœŃ‹Ń… ĐżŃ€ĐŸĐžĐ·ĐČĐŸĐŽĐœŃ‹Ń…Ń‹Ń… ĐČ ĐșачДстĐČĐ” ĐŒĐŸĐŽŃƒĐ»ŃŃ‚ĐŸŃ€ĐŸĐČ ĐŒŃƒŃĐșĐ°Ń€ĐžĐœĐŸĐČых Ń€Đ”Ń†Đ”ĐżŃ‚ĐŸŃ€ĐŸĐČ
EP1694686A1 (en) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
AU2005212438A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20080050314A1 (en) * 2004-02-26 2008-02-28 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated With Glycogen Synthase Kinase 3 Beta (Gsk3b)
EP1726580A4 (en) * 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
JP4790703B2 (ja) * 2004-04-07 2011-10-12 æ­Šç”°è–Źć“ć·„æ„­æ ȘćŒäŒšç€Ÿ ç’°ćŒćŒ–ćˆç‰©
JP2007533717A (ja) * 2004-04-21 2007-11-22 ケă‚čăƒˆăƒ©ă‚Œăƒă‚« ă‚ąă‚Żăƒăƒœăƒ©ă‚° ćŒ–ćˆç‰©
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
EP1751136B1 (en) * 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
AU2012200416B2 (en) * 2004-05-14 2014-07-31 Millennium Pharmaceuticals, Inc. "Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase"
US20050255485A1 (en) * 2004-05-14 2005-11-17 Livak Kenneth J Detection of gene duplications
MXPA06013208A (es) * 2004-05-14 2007-01-16 Vertex Pharma Profarmacos de pirrolipirimidina como inhibidotes de la proteina cinasa erk.
SI1771450T1 (sl) * 2004-05-14 2008-06-30 Millennium Pharm Inc Spojine in postopki za inhibiranje mitotične progresije z inhibicijo kinaze Aurora
ES2299080T3 (es) * 2004-05-14 2008-05-16 Millennium Pharmaceuticals, Inc. Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora.
EP1750698A4 (en) * 2004-05-20 2010-06-02 Bayer Pharmaceuticals Corp 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
US20050282094A1 (en) * 2004-05-27 2005-12-22 Kim Young H Developer for a photopolymer protective layer
JP4990766B2 (ja) * 2004-07-01 2012-08-01 ă‚·ăƒłă‚ż ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚łăƒŒăƒăƒŹăƒŒă‚·ăƒ§ăƒł äșŒçœźæ›ćž‹ăƒ˜ăƒ†ăƒ­ă‚ąăƒȘăƒŒăƒ«ćŒ–ćˆç‰©
JP2008505907A (ja) * 2004-07-06 2008-02-28 ケンゾă‚Șン ăƒă‚€ă‚ȘăƒĄăƒ‡ă‚Łă‚« ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒł 癌æČ»ç™‚ă‚’ç›źçš„ăšă—ăŠè‚çŽ°èƒžćą—æź–ć› ć­ăŠă‚ˆăłïœƒâˆ’ïœïœ…ïœ”æŽ»æ€§ă‚’èȘżæ•Žă™ă‚‹ă‚­ăƒŠă‚ŸăƒȘăƒłăƒąă‚žăƒ„ăƒŹăƒŒă‚żăƒŒ
JP2008510734A (ja) 2004-08-18 2008-04-10 ă‚żă‚±ăƒ€ ă‚”ăƒł ディスギ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ă‚­ăƒŠăƒŒă‚Œé˜»ćźłć‰€
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
AR050948A1 (es) 2004-09-24 2006-12-06 Hoffmann La Roche Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
AU2005288865B2 (en) * 2004-09-30 2012-07-19 Janssen Sciences Ireland Uc HIV inhibiting 5-carbo- or heterocyclic substituted pyrimidines
WO2006035067A2 (en) * 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-heterocyclyl pyrimidines
ES2380631T3 (es) * 2004-09-30 2012-05-17 Tibotec Pharmaceuticals Pirimidinas sustituidas en posiciĂłn 5 inhibidoras de VIH
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
US20080027042A1 (en) * 2004-10-29 2008-01-31 Mitsuru Ohkubo Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action
JP2008519034A (ja) 2004-11-03 2008-06-05 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ă‚€ă‚ȘăƒłăƒăƒŁăƒăƒ«èȘżçŻ€ć‰€ăšă—ăŠăźăƒ”ăƒȘミゾンèȘ˜ć°Žäœ“ăŠă‚ˆăłäœżç”šæ–čæł•
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
WO2006067614A2 (en) * 2004-12-23 2006-06-29 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
US8110573B2 (en) * 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
US8211929B2 (en) 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
JP4804480B2 (ja) * 2005-01-26 2011-11-02 ă‚·ă‚§ăƒŒăƒȘング ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒł ç™Œăźć‡ŠçœźăźăŸă‚ăźăƒ—ăƒ­ăƒ†ă‚€ăƒłă‚­ăƒŠăƒŒă‚Œă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒăšă—ăŠăźă€ïŒ“âˆ’ïŒˆă‚€ăƒłăƒ€ă‚ŸăƒŒăƒ«âˆ’ïŒ•âˆ’ă‚€ăƒ«ïŒ‰âˆ’ïŒˆïŒ‘ïŒŒïŒ’ïŒŒïŒ”ïŒ‰ăƒˆăƒȘケゾンèȘ˜ć°Žäœ“ă€ăŠă‚ˆăłé–ąé€Łă™ă‚‹ćŒ–ćˆç‰©
PT1846394E (pt) 2005-02-04 2012-01-05 Astrazeneca Ab Derivados de pirazolilaminopiridina Ășteis como inibidores da quinase
AU2006215394B2 (en) * 2005-02-16 2009-10-08 Astrazeneca Ab Chemical compounds
ES2308731T3 (es) * 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
BRPI0608513A2 (pt) * 2005-03-15 2010-01-05 Irm Llc compostos e composiçÔes como inibidores da proteÏna quinase
JP2008534481A (ja) * 2005-03-23 2008-08-28 ケă‚čăƒˆăƒ©ă‚Œăƒă‚« ă‚ąă‚Żăƒăƒœăƒ©ă‚° ă‚€ăƒłă‚čăƒȘăƒłæ§˜ćą—æź–ć› ć­âˆ’ïŒ‘ć—ćźčäœ“æŽ»æ€§ăźé˜»ćźłć‰€ăšă—ăŠăźïŒ’âˆ’ă‚ąă‚Œăƒă‚žăƒ‹ăƒ«âˆ’ïŒ”âˆ’ïŒˆïŒ‘ïœˆâˆ’ăƒ”ăƒ©ă‚ŸăƒŒăƒ«âˆ’ïŒ“âˆ’ă‚€ăƒ«ă‚ąăƒŸăƒŽïŒ‰ăƒ”ăƒȘミゾン
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
JP2008534662A (ja) * 2005-04-05 2008-08-28 ケă‚čăƒˆăƒ©ă‚Œăƒă‚« ă‚ąă‚Żăƒăƒœăƒ©ă‚° æŠ—ç™Œć‰€ăšă—ăŠäœżç”šă•ă‚Œă‚‹ăƒ”ăƒȘミゾンèȘ˜ć°Žäœ“
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds
US7462639B2 (en) 2005-04-14 2008-12-09 Hoffmann-La Roche Inc. Aminopyrazole derivatives
WO2006115452A1 (en) * 2005-04-27 2006-11-02 Astrazeneca Ab Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
WO2006118231A1 (ja) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation ă‚·ă‚ąăƒŽăƒ”ăƒȘゾンèȘ˜ć°Žäœ“ćŠăłăăźćŒ»è–Źăšă—ăŠăźç”šé€”
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
WO2006119504A2 (en) 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
JP2008540391A (ja) * 2005-05-05 2008-11-20 ケă‚čăƒˆăƒ©ă‚Œăƒă‚« ă‚ąă‚Żăƒăƒœăƒ©ă‚° ăƒ”ăƒ©ă‚ŸăƒȘăƒ«ă‚ąăƒŸăƒŽçœźæ›ăƒ”ăƒȘăƒŸă‚žăƒłă€ăŠă‚ˆăłç™Œăźć‡Šçœźă«ăŠă‘ă‚‹ăă‚Œă‚‰ăźäœżç”š
AU2006248780B2 (en) * 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
RU2485106C2 (ru) 2005-06-08 2013-06-20 Đ Đ°ĐčЎжДл Đ€Đ°ĐŒŃŃŃŒŃŽŃ‚ĐžĐșŃĐ»Đ·, Đ˜ĐœĐș. ĐĄĐŸĐ”ĐŽĐžĐœĐ”ĐœĐžŃ, ĐżŃ€ĐŸŃĐČĐ»ŃŃŽŃ‰ĐžĐ” Đ°ĐșтоĐČĐœĐŸŃŃ‚ŃŒ ĐČ ĐŸŃ‚ĐœĐŸŃˆĐ”ĐœĐžĐž jak-ĐșĐžĐœĐ°Đ·Ń‹ (ĐČĐ°Ń€ĐžĐ°ĐœŃ‚Ń‹), ŃĐżĐŸŃĐŸĐ± Đ»Đ”Ń‡Đ”ĐœĐžŃ Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžĐč, ĐŸĐżĐŸŃŃ€Đ”ĐŽĐŸĐČĐ°ĐœĐœŃ‹Ń… jak-ĐșĐžĐœĐ°Đ·ĐŸĐč, ŃĐżĐŸŃĐŸĐ± ĐžĐœĐłĐžĐ±ĐžŃ€ĐŸĐČĐ°ĐœĐžŃ Đ°ĐșтоĐČĐœĐŸŃŃ‚Đž jak-ĐșĐžĐœĐ°Đ·Ń‹ (ĐČĐ°Ń€ĐžĐ°ĐœŃ‚Ń‹), Ń„Đ°Ń€ĐŒĐ°Ń†Đ”ĐČтОчДсĐșая ĐșĐŸĐŒĐżĐŸĐ·ĐžŃ†ĐžŃ ĐœĐ° ĐŸŃĐœĐŸĐČĐ” уĐșĐ°Đ·Đ°ĐœĐœŃ‹Ń… ŃĐŸĐ”ĐŽĐžĐœĐ”ĐœĐžĐč
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EP1890703B1 (en) 2005-06-14 2016-05-11 Taigen Biotechnology Pyrimidine compounds as chemokine receptors inhibitors
EP1746096A1 (en) 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
EP1917259B1 (en) * 2005-08-18 2012-01-25 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
ES2535854T3 (es) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
UA96427C2 (en) * 2005-09-30 2011-11-10 МоĐčĐșĐ°ĐœĐ° ĐąĐ”Ń€Đ°ĐżŃŒŃŽŃ‚ĐžĐșс, Đ˜ĐœĐș. Substituted pyrazole compounds
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009512711A (ja) 2005-10-21 2009-03-26 ăƒ–ăƒŹă‚€ăƒłă‚»ăƒ«ă‚čïŒŒă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ă‚Łăƒ‰ ïŒ°ïœ„ïœ…é˜»ćźłă«ă‚ˆă‚‹ç„žç”Œæ–°ç”ŸăźèȘżçŻ€
WO2007049041A1 (en) * 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
AU2006309173B2 (en) * 2005-11-01 2011-08-18 Array Biopharma Inc. Glucokinase activators
CN101316597B (zh) * 2005-11-03 2013-04-17 饶ç‚čćŒ»èŻć“ć…Źćž ç”šäœœæż€é…¶æŠ‘ćˆ¶ć‰‚çš„æ°šćŸșć˜§ć•¶
DE602006021776D1 (de) * 2005-11-16 2011-06-16 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
EP1968579A1 (en) 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
US20080058312A1 (en) * 2006-01-11 2008-03-06 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
JO2660B1 (en) 2006-01-20 2012-06-17 Ù†ÙˆÙŰ§Ű±ŰȘÙŠŰł Ű§ÙŠÙ‡ ŰŹÙŠ Pi-3 inhibitors and methods of use
ES2353437T3 (es) * 2006-02-16 2011-03-02 Schering Corporation Derivados de pirrolidina como inhibidores de erk.
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
WO2007113254A1 (en) * 2006-03-30 2007-10-11 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-amido substituted pyrimidines
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
US20090286803A1 (en) 2006-04-07 2009-11-19 Manley Paul W Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
BRPI0710737A2 (pt) 2006-04-14 2011-05-10 Prana Biotechnology Ltd uso de compostos pb-10 33 Ă©teis para o tratamento de degeneraÇço macular relacionada À idade (amd), assim como referidos compostos
EP2017279B1 (en) * 2006-04-27 2013-09-04 Msd K.K. Aminopyrimidine derivatives having aurora-a-selective inhibitory activity
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2838448A1 (en) 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
JP2009542608A (ja) * 2006-06-29 2009-12-03 ケă‚čテックă‚čăƒ»ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č・ăƒȘミテッド ćŒ»è–Źç”„ćˆă›ć‰€
JP5523829B2 (ja) 2006-06-29 2014-06-18 ケă‚čテックă‚čă€ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łăƒƒă‚Żă‚č、ăƒȘミテッド è€‡ćˆè–Źć‰€
WO2008001886A1 (en) * 2006-06-30 2008-01-03 Kyowa Hakko Kirin Co., Ltd. Aurora inhibitor
UY30444A1 (es) * 2006-06-30 2008-01-31 Astrazeneca Ab Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
CA2656290A1 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2054413A2 (en) * 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
US7832809B2 (en) * 2006-08-11 2010-11-16 Schlumberger Technology Corporation Degradation assembly shield
JP2008081492A (ja) * 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd ă‚ȘăƒŒăƒ­ăƒ©ïœéžæŠžçš„é˜»ćźłäœœç”šă‚’æœ‰ă™ă‚‹æ–°èŠă‚ąăƒŸăƒŽăƒ”ăƒȘゾンèȘ˜ć°Žäœ“
JP2010502722A (ja) * 2006-09-08 2010-01-28 ăƒ–ăƒŹă‚€ăƒłă‚»ăƒ«ă‚čïŒŒă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ă‚Łăƒ‰ ïŒ”âˆ’ă‚ąă‚·ăƒ«ă‚ąăƒŸăƒŽăƒ”ăƒȘゾンèȘ˜ć°Žäœ“ă‚’ć«ă‚€ç”„ăżćˆă‚ă›
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2223925A1 (en) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 æ­Šç”°è–Źć“ć·„æ„­æ ȘćŒäŒšç€Ÿ ă‚­ăƒŠăƒŒă‚Œé˜»ćźłć‰€
JP5528806B2 (ja) 2006-10-12 2014-06-25 ケă‚čテックă‚čă€ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łăƒƒă‚Żă‚č、ăƒȘミテッド è€‡ćˆè–Źć‰€
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008053812A1 (en) * 2006-10-27 2008-05-08 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and medicinal use thereof
EP2086965B1 (en) 2006-11-02 2010-02-10 Vertex Pharmaceuticals, Inc. Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AU2007333650A1 (en) 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
WO2008080965A2 (en) * 2006-12-29 2008-07-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5,6-substituted pyrimidines
JP5185283B2 (ja) * 2006-12-29 2013-04-17 ăƒ†ă‚€ăƒœăƒ†ă‚Żăƒ»ăƒ•ă‚ąăƒŒăƒžă‚·ăƒŠăƒŒăƒă‚«ăƒ«ă‚ș ïŒšïœ‰ïœ–é˜»ćźłïŒ–âˆ’çœźæ›ăƒ”ăƒȘミゾン
EP2118087B1 (en) 2007-02-06 2012-03-28 Novartis AG Pi 3-kinase inhibitors and methods of their use
WO2008111441A1 (ja) 2007-03-05 2008-09-18 Kyowa Hakko Kirin Co., Ltd. ćŒ»è–Źç”„æˆç‰©
JP5393489B2 (ja) * 2007-03-09 2014-01-22 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ è›‹ç™œă‚­ăƒŠăƒŒă‚Œăźé˜»ćźłć‰€ăšă—ăŠæœ‰ç”šăȘケミノピăƒȘミゾン
JP2010520887A (ja) 2007-03-09 2010-06-17 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ è›‹ç™œă‚­ăƒŠăƒŒă‚Œăźé˜»ćźłć‰€ăšă—ăŠæœ‰ç”šăȘケミノピăƒȘゾン
MX2009009590A (es) 2007-03-09 2009-11-10 Vertex Pharma Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009010037A (es) * 2007-03-20 2009-11-05 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasas.
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CN101679429A (zh) * 2007-04-18 2010-03-24 é˜żæ–Żćˆ©ćș·(瑞慾)æœ‰é™ć…Źćž 5-æ°šćŸș搡攑-3-ćŸș-3h-ć’Ș攑ćč¶[4,5-b]ćĄć•¶èĄç”Ÿç‰©ćŠć…¶æČ»ç–—ç™Œçš„ç”šé€”
JP4782239B2 (ja) 2007-04-18 2011-09-28 ăƒ•ă‚Ąă‚€ă‚¶ăƒŒăƒ»ăƒ—ăƒ­ăƒ€ă‚Żăƒ„ăƒ»ă‚€ăƒłă‚Ż ç•°ćžžçŽ°èƒžćą—æź–æČ»ç™‚ăźăŸă‚ăźă‚čăƒ«ăƒ›ăƒ‹ăƒ«ă‚ąăƒŸăƒ‰èȘ˜ć°Žäœ“
JP5389785B2 (ja) * 2007-05-02 2014-01-15 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ă‚­ăƒŠăƒŒă‚Œé˜»ćźłć‰€ăšă—ăŠæœ‰ç”šăȘăƒă‚ąă‚ŸăƒŒăƒ«ăŠă‚ˆăłăƒ”ăƒ©ă‚ŸăƒŒăƒ«
CA2694381A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
MX2009011811A (es) * 2007-05-02 2010-01-14 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
UA99459C2 (en) * 2007-05-04 2012-08-27 ĐŃŃ‚Ń€Đ°Đ·Đ”ĐœĐ”ĐșĐ° Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
ATE521609T1 (de) * 2007-05-04 2011-09-15 Astrazeneca Ab Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
CN101687852A (zh) * 2007-05-24 2010-03-31 æČƒæł°ć…‹æ–ŻèŻç‰©è‚Ąä»œæœ‰é™ć…Źćž ćŻç”šäœœæż€é…¶æŠ‘ćˆ¶ć‰‚çš„ć™»ć”‘ç±»ć’ŒćĄć”‘ç±»ćŒ–ćˆç‰©
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삌성디슀플레읎 ìŁŒì‹íšŒì‚Ź 얎레읎 Ʞ판, 읎넌 갖는 표시팚널 및 읎의 ì œìĄ°ë°©ëȕ
CA2683152A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
JP2010532756A (ja) * 2007-07-06 2010-10-14 ă‚ȘăƒŒă‚šă‚čă‚ąă‚€ăƒ»ăƒ•ă‚ĄăƒŒăƒžă‚čăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹăƒŒăƒ†ăƒƒăƒ‰ ïœïŒŽïŒŻïŒČïŒŁïŒ‘ćŠăłïœïŒŽïŒŻïŒČïŒŁïŒ’ăźäžĄæ–čăźé˜»ćźłć‰€ă‚’ć«ă‚€ç”„ăżćˆă‚ă›æŠ—ç™Œç™‚æł•
WO2009007753A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
KR20100038108A (ko) * 2007-07-25 2010-04-12 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 íŠžëŠŹì•„ì§„ 킀나제 얔제제
WO2009013545A2 (en) * 2007-07-26 2009-01-29 Astrazeneca Ab Chemical compounds
CN101790532B (zh) * 2007-07-31 2013-11-20 æČƒæł°ć…‹æ–ŻèŻç‰©è‚Ąä»œæœ‰é™ć…Źćž 5-氟-1H-搡攑ćč¶[34-b]搥敶-3-èƒșćŠć…¶èĄç”Ÿç‰©çš„ćˆ¶ć€‡æ–čæł•
TW200906818A (en) * 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009027736A2 (en) * 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
BRPI0816881A2 (pt) 2007-09-21 2015-03-17 Array Biopharma Inc Composto, composição farmacĂȘutica, uso de um composto, e, mĂ©todos para tratar doenças ou distĂșrbios e para preparar um composto.
CA2702265C (en) 2007-10-11 2014-12-02 Smithkline Beecham Corporation Novel seh inhibitors and their use
US8288397B2 (en) 2007-12-17 2012-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
SG188179A1 (en) * 2008-02-21 2013-03-28 Merck Sharp & Dohme Compounds that are erk inhibitors
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
PL2268635T3 (pl) 2008-04-21 2015-11-30 Taigen Biotechnology Co Ltd Związki heterocykliczne
WO2010011411A1 (en) 2008-05-27 2010-01-28 The Trustees Of Columbia University In The City Of New York Systems, methods, and media for detecting network anomalies
AU2009259026B2 (en) * 2008-06-11 2012-10-04 Astrazeneca Ab Tricyclic 2,4-diamin0-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
KR20110046514A (ko) * 2008-07-31 2011-05-04 ì œë„ší…ŒíŹ, ìžíŹ. í”ŒëŠŹëŻžë”˜ í™”í•©ëŹŒ, ìĄ°ì„±ëŹŒ 및 ì‚Źìš© ë°©ëȕ
WO2010027921A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
CN105574346A (zh) * 2008-09-05 2016-05-11 新ćŸșé˜żç»Žçœ—ç±łć…‹æ–Żç ”ç©¶ć…Źćž ć€šè‚œć¶è”ç‰©äžŽäžćŻé€†æŠ‘ćˆ¶ć‰‚çš„èźŸèźĄæ–čæł•ć’ŒæŁ€æ”‹æ–čæł•
WO2010031056A2 (en) * 2008-09-15 2010-03-18 The Regents Of The University Of California Methods and compositions for modulating ire1, src, and abl activity
KR20110071098A (ko) * 2008-09-30 2011-06-28 아슀튞띌제넀ìčŽ ì•„ëČ  ëł”ì†Œí™˜  킀나제 얔제제
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
WO2010056758A1 (en) * 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
TW201021855A (en) 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
EP2373664B1 (en) * 2008-12-19 2013-06-12 Nerviano Medical Sciences S.r.l. Bicyclic pyrazoles as protein kinase inhibitors
WO2010074724A1 (en) 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
US8809343B2 (en) 2008-12-26 2014-08-19 Fudan University Pyrimidine derivative, preparation method and use thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
RU2529019C2 (ru) * 2009-02-27 2014-09-27 Đ­ĐŒĐ±ĐžŃ‚ БаĐčĐŸŃĐ°ĐčĐ”ĐœŃĐžĐ· ĐšĐŸŃ€ĐżĐŸŃ€Đ”ĐčŃˆĐœ ĐœĐŸĐŽŃƒĐ»ĐžŃ€ŃƒŃŽŃ‰ĐžĐ” jak ĐșĐžĐœĐ°Đ·Ńƒ Ń…ĐžĐœĐ°Đ·ĐŸĐ»ĐžĐœĐŸĐČŃ‹Đ” ĐżŃ€ĐŸĐžĐ·ĐČĐŸĐŽĐœŃ‹Đ” Đž ŃĐżĐŸŃĐŸĐ±Ń‹ ох ĐżŃ€ĐžĐŒĐ”ĐœĐ”ĐœĐžŃ
CA2660962A1 (en) 2009-03-31 2010-09-30 Astellas Pharma Inc. Novel pharmaceutical composition for treatment of schizophrenia
US8399663B2 (en) 2009-04-03 2013-03-19 Astellas Pharma Inc. Salt of 1,3,5-triazine-2,4,6-triamine derivative
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc Ù…Ű±ÙƒŰšŰ§ŰȘ Ű”ÙŠŰŻÙ„Ű§Ù†ÙŠŰ© Ű”Ù„ŰšŰ© ÙˆŰ·Ű±Ù‚ Ù„Ű§Ù†ŰȘŰ§ŰŹÙ‡Ű§
AU2010259002B2 (en) * 2009-06-08 2014-03-20 Nantbio, Inc. Triazine derivatives and their therapeutical applications
EP2440052A4 (en) * 2009-06-08 2013-01-23 Abraxis Bioscience Llc TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
BRPI1011319A2 (pt) * 2009-06-09 2016-06-21 California Capital Equity Llc derivados de triazina benzil-substituĂ­dos e suas aplicaçÔes terapĂȘuticas
AU2010258853B2 (en) * 2009-06-09 2014-07-31 Nantbio, Inc. Triazine derivatives and their therapeutical applications
KR20120026613A (ko) * 2009-06-09 2012-03-19 아람띜시슀 ë°”ìŽì˜€ì‚ŹìŽì–žìŠ€, 엘엘씚 슀티늎-íŠžëŠŹì•„ì§„ 유도ìČŽì™€ 읎듀의 ìč˜ëŁŒì  용도
US20120202818A1 (en) * 2009-06-09 2012-08-09 California Capital Equity, Llc Ureidophenyl substituted triazine derivatives and their therapeutical applications
US20120172384A1 (en) * 2009-06-18 2012-07-05 Mihiro Sunose Heterocyclylaminopyrimidines as kinase inhibitors
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) * 2009-07-31 2015-01-11 濅æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž 降䜎ÎČïŒéĄžæŸ±çČ‰ç”Ÿæˆäč‹ćŒ–ćˆç‰©
CN102482312A (zh) 2009-08-26 2012-05-30 è”›èŻșèČ æ–°éą–çš„æ‚èŠłæ—æ°Ÿä»Łçł–è‹·ç»“æ™¶æ°Žćˆç‰©ă€ć«æœ‰èż™äș›ćŒ–ćˆç‰©çš„èŻç‰©ć’Œćźƒä»Źçš„ç”šé€”
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
US8876857B2 (en) * 2009-11-13 2014-11-04 Intuitive Surgical Operations, Inc. End effector with redundant closing mechanisms
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
CN102812167A (zh) 2009-12-30 2012-12-05 é˜żç»Žæ‹‰ćˆ¶èŻć…Źćž 蛋癜的配䜓-ä»‹ćŻŒçš„ć…±ä»·äżźé„°
SA111320200B1 (ar) * 2010-02-17 2014-02-16 ŰŻÙŠŰšÙŠÙˆÙŰ§Ű±Ù… ۧ۳ Ű§ÙŠÙ‡ Ù…Ű±ÙƒŰšŰ§ŰȘ Ű«Ù†Ű§ŰŠÙŠŰ© Ű§Ù„Ű­Ù„Ù‚Ű© ÙˆŰ§ŰłŰȘŰźŰŻŰ§Ù…Ű§ŰȘÙ‡Ű§ ÙƒÙ…Ű«ŰšŰ·Ű§ŰȘ c-src/jak مŰČŰŻÙˆŰŹŰ©
US8653064B2 (en) 2010-02-19 2014-02-18 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2571359A4 (en) * 2010-05-20 2013-10-23 Merck Sharp & Dohme NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
WO2011144742A1 (en) 2010-05-21 2011-11-24 Chemilia Ab Novel pyrimidine derivatives
MX2012014158A (es) 2010-06-04 2013-02-07 Hoffmann La Roche Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US20130225615A1 (en) * 2010-09-01 2013-08-29 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
JP5872558B2 (ja) * 2010-09-01 2016-03-01 ケムビト ビă‚Șă‚čă‚·ă‚šăƒłă‚»ă‚č ă‚łăƒ«ăƒăƒ©ăƒă‚Șン ăƒ”ăƒ©ă‚ŸăƒȘăƒ«ă‚ąăƒŸăƒŽă‚­ăƒŠă‚ŸăƒȘăƒłăźè‡­ćŒ–æ°ŽçŽ é…žćĄ©
WO2012030918A1 (en) * 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
EP2611794A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
CA2810024A1 (en) * 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
US20130296363A1 (en) * 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
EP2611796B1 (en) 2010-09-01 2016-04-20 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
ES2653967T3 (es) 2010-11-10 2018-02-09 Genentech, Inc. Derivados de pirazol aminopirimidina como moduladores de LRRK2
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
EP2748159A1 (en) * 2011-08-25 2014-07-02 F.Hoffmann-La Roche Ag Serine/threonine pak1 inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103814030A (zh) * 2011-09-22 2014-05-21 èŸ‰ç‘žć€§èŻćŽ‚ 搡撯ćč¶ć˜§ć•¶ćŠć˜Œć‘€èĄç”Ÿç‰©
JP6026544B2 (ja) 2011-09-27 2016-11-16 ăƒŽăƒăƒ«ăƒ†ă‚Łă‚č ă‚ąăƒŒă‚ČăƒŒ ć€‰ç•°äœ“ïœ‰ïœ„ïœˆăźé˜»ćźłć‰€ăšă—ăŠăźïŒ“âˆ’ăƒ”ăƒȘăƒŸă‚žăƒłâˆ’ïŒ”âˆ’ă‚€ăƒ«âˆ’ă‚Șă‚­ă‚”ă‚ŸăƒȘă‚žăƒłâˆ’ïŒ’âˆ’ă‚Șン類
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US8815877B2 (en) 2011-12-22 2014-08-26 Genentech, Inc. Serine/threonine kinase inhibitors
JP6141334B2 (ja) * 2012-02-17 2017-06-07 ă‚ąăƒƒăƒŽă‚Łăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ăƒ’ăƒˆć‘Œćžć™šć€šæ žäœ“ă‚Šă‚€ăƒ«ă‚čïŒˆïœ’ïœ“ïœ–ïŒ‰ăźé˜»ćźłć‰€ăšă—ăŠæœ‰ç”šăȘゾケミノピăƒȘミゾン
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
SG11201405761WA (en) 2012-03-16 2014-10-30 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
EP2841428B1 (en) 2012-04-24 2018-08-22 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
CA2875990A1 (en) * 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9216991B2 (en) * 2012-07-10 2015-12-22 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
CA2884731C (en) * 2012-09-19 2016-11-01 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration with improved dissolution and/or absorption
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN103191120B (zh) * 2012-12-31 2015-11-25 战ćŒș äž€ç§ć˜§ć•¶èĄç”Ÿç‰©ćœšćˆ¶ć€‡éą„é˜Č撌/或æČ»ç–—ć’Œ/æˆ–èŸ…ćŠ©æČ»ç–—è‚żç˜€çš„èŻç‰©äž­çš„ç”šé€”
CN103059002B (zh) * 2012-12-31 2015-04-22 䞭汱性歊 ć…·æœ‰Auroraæż€é…¶æŠ‘ćˆ¶æŽ»æ€§çš„ć˜§ć•¶èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ä»„ćŠćș”甚
CN103202843B (zh) * 2012-12-31 2015-04-29 战ćŒș äž€ç§ć˜§ć•¶èĄç”Ÿç‰©ćœšćˆ¶ć€‡éą„é˜Č撌/或æČ»ç–—ć’Œ/æˆ–èŸ…ćŠ©æČ»ç–—ç™Œç—‡çš„èŻç‰©äž­çš„ç”šé€”
CN103910716A (zh) * 2013-01-07 2014-07-09 ćŽäžœç†ć·„ć€§ć­Š 2,4-äșŒć–代-çŽŻçƒ·ćŸș[d]ć˜§ć•¶ç±»ćŒ–ćˆç‰©ćŠć…¶ç”šé€”
WO2014159690A1 (en) 2013-03-12 2014-10-02 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
HK1213251A1 (zh) 2013-03-14 2016-06-30 Novartis Ag 䜜äžșçȘć˜idhæŠ‘ćˆ¶ć‰‚çš„3-ć˜§ć•¶-4-ćŸș-æ¶ć”‘çƒ·-2-é…źćŒ–ćˆç‰©
EP3842424B1 (en) 2013-03-15 2024-12-11 The Trustees of Columbia University in the City of New York Map kinase modulators and uses thereof in the tretament of tauopathies
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2015028848A1 (en) * 2013-09-02 2015-03-05 Piramal Enterprises Limited Bicyclic heterocyclic compounds as multi-kinase inhibitors
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
PL3424920T3 (pl) 2013-10-17 2020-11-16 Vertex Pharmaceuticals Incorporated KokrysztaƂy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
JP6491202B2 (ja) 2013-10-18 2019-03-27 ăƒ‡ă‚€ăƒŠ ăƒ•ă‚ĄăƒŒăƒăƒŒ ă‚­ăƒŁăƒłă‚”ăƒŒ ă‚€ăƒłă‚čăƒ†ă‚Łăƒăƒ„ăƒŒăƒˆïŒŒă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ゔむクăƒȘăƒłäŸć­˜æ€§ă‚­ăƒŠăƒŒă‚ŒïŒ—ïŒˆïœƒïœ„ïœ‹ïŒ—ïŒ‰ăźć€šç’°é˜»ćźłć‰€
CA2935392C (en) 2014-01-01 2022-07-26 Medivation Technologies, Inc. Amino pyridine derivatives for the treatment of conditions associated with excessive tgf.beta activity
PT3116475T (pt) 2014-03-13 2020-12-15 Neuroderm Ltd ComposiçÔes de inibidores de dopa-descarboxilase
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
WO2015148868A1 (en) * 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CA2944240A1 (en) 2014-04-04 2015-10-08 Iomet Pharma Ltd Indole derivatives as ido/tdo inhibitors
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN105367555B (zh) * 2014-08-07 2019-06-25 ćčżäžœäžœé˜łć…‰èŻäžšæœ‰é™ć…Źćž ć–ä»Łçš„æ‚èŠłćŸșćŒ–ćˆç‰©ćŠć…¶ç»„ćˆç‰©ć’Œç”šé€”
TWI730331B (zh) 2014-10-13 2021-06-11 ć—éŸ“ć•†æŸłéŸ“æŽ‹èĄŒè‚Ąä»œæœ‰é™ć…Źćž 甚斌èȘżçŻ€ïœ…çȘèźŠćž‹æż€é…¶æŽ»æ€§çš„ćŒ–ćˆç‰©ćŠç”„æˆç‰©
HUE049801T2 (hu) 2014-12-23 2020-10-28 Sma Therapeutics Inc 3,5-diaminopirazol kinĂĄz inhibitorok
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016123627A1 (en) * 2015-01-30 2016-08-04 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
EP3283482B1 (en) 2015-04-17 2022-04-06 Ludwig Institute for Cancer Research Ltd Plk4 inhibitors
PL3303348T3 (pl) 2015-05-28 2020-02-28 Theravance Biopharma R&D Ip, Llc Związki naftyrydyny jako inhibitory kinazy JAK
JP2018135268A (ja) * 2015-06-05 2018-08-30 ć€§æ—„æœŹäœć‹èŁœè–Źæ ȘćŒäŒšç€Ÿ æ–°èŠăƒ˜ăƒ†ăƒ­ă‚ąăƒȘăƒŒăƒ«ă‚ąăƒŸăƒŽâˆ’ïŒ“âˆ’ăƒ”ăƒ©ă‚ŸăƒŒăƒ«èȘ˜ć°Žäœ“ăŠă‚ˆăłăăźè–Źç†ć­ŠäžŠèš±ćźčă•ă‚Œă‚‹ćĄ©
JP2018524292A (ja) 2015-07-21 2018-08-30 ミレニケム ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ïŒ­ïœ‰ïœŒïœŒïœ…ïœŽïœŽïœ‰ïœ•ïœ   ă‚ȘăƒŒăƒ­ăƒ©ă‚­ăƒŠăƒŒă‚Œă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒăšćŒ–ć­Šç™‚æł•ć‰€ăźæŠ•äžŽ
JP7028766B2 (ja) 2015-09-09 2022-03-02 ăƒ€ăƒŠïŒăƒ•ă‚ĄăƒŒăƒăƒŒ ă‚­ăƒŁăƒłă‚”ăƒŒ ă‚€ăƒłă‚čăƒ†ă‚Łăƒ†ăƒ„ăƒŒăƒˆïŒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ゔむクăƒȘăƒłäŸć­˜æ€§ă‚­ăƒŠăƒŒă‚Œăźé˜»ćźłć‰€
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
CN108697709A (zh) * 2015-12-10 2018-10-23 PtcćŒ»ç–—ć…Źćž 甹äșŽæȻ疗äșšć»·éĄżç—…çš„æ–čæł•
CN105384702B (zh) * 2015-12-11 2018-04-10 æ”™æ±Ÿć€§ć­Š äž‰ć–ä»Łć‡äž‰ć—Șç±»ćŒ–ćˆç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•
CN105503754B (zh) * 2015-12-11 2017-11-17 æ”™æ±Ÿć€§ć­Š 2‑氚ćŸș‑4‑苄ćŸș‑6‑搗敉‑1,3,5‑侉ć—ȘćŠć…¶ćˆ¶ć€‡ć’Œćș”甚
CN105399695B (zh) * 2015-12-11 2019-04-19 æ”™æ±Ÿć€§ć­Š 侉ć—Șç±»ćŒ–ćˆç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
AU2017233841B9 (en) 2016-03-14 2021-09-09 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
CA3018180C (en) * 2016-03-25 2024-02-20 Ronald Charles Hawley Pyrimidines and variants thereof, and uses therefor
CN109071529B (zh) 2016-04-28 2021-08-06 æ–œäž‡ç”Ÿç‰©ćˆ¶èŻç ”ć‘Ipæœ‰é™èŽŁä»»ć…Źćž 䜜äžșjakæż€é…¶æŠ‘ćˆ¶ć‰‚çš„ć˜§ć•¶ćŒ–ćˆç‰©
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
WO2018064092A1 (en) 2016-09-27 2018-04-05 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
US10858319B2 (en) 2016-10-03 2020-12-08 Iomet Pharma Ltd. Indole derivatives for use in medicine
US10968227B2 (en) * 2016-11-08 2021-04-06 Vanderbilt University Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN108239071B (zh) * 2016-12-27 2020-12-04 æČˆé˜łèŻç§‘ć€§ć­Š 酰èƒșćŠçĄ«ä»Łé…°èƒșç±»èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚
FR3064275B1 (fr) 2017-03-21 2019-06-07 Arkema France Procede de chauffage et/ou climatisation d'un vehicule
IL270873B2 (en) 2017-05-30 2023-04-01 Basf Se "The history of pyridine and pyrazine compounds, a preparation containing them and their use as fungicides
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
CN111182898B (zh) 2017-06-28 2024-04-16 PtcćŒ»ç–—ć…Źćž 甹äșŽæȻ疗äșšć»·éĄżæ°ç—…çš„æ–čæł•
EP3421465B1 (en) * 2017-06-30 2022-10-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
JP7311228B2 (ja) 2017-06-30 2023-07-19 ăƒ™ă‚€ă‚žăƒł ă‚żă‚€ăƒ‰ ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ« ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ăƒȘミテッド ïŒČïœˆïœïŒé–ąé€Łăƒ—ăƒ­ăƒ†ă‚€ăƒłă‚­ăƒŠăƒŒă‚Œé˜»ćźłć‰€ă€ăă‚Œă‚’ć«ă‚€ćŒ»è–Źç”„æˆç‰©äžŠăłă«ăăźèȘżèŁœæ–čæł•ćŠăłäœżç”š
WO2019000683A1 (zh) 2017-06-30 2019-01-03 挗äșŹæł°ćŸ·ćˆ¶èŻè‚Ąä»œæœ‰é™ć…Źćž Rhoç›žć…łè›‹ç™œæż€é…¶æŠ‘ćˆ¶ć‰‚ă€ćŒ…ć«ć…¶çš„èŻç‰©ç»„ćˆç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
EP3676264A1 (en) * 2017-08-28 2020-07-08 Acurastem Inc. Pikfyve kinase inhibitors
US11440904B2 (en) * 2017-08-28 2022-09-13 Zhihong Chen Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
CA3074034A1 (en) 2017-10-27 2019-05-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compound as jak kinase inhibitor
EP3672957A1 (en) * 2017-11-23 2020-07-01 BioMed X GmbH Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors
WO2019113311A1 (en) * 2017-12-06 2019-06-13 Ludwig Institute For Cancer Research Ltd Methods of treating cancer with plk4 inhibitors
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
WO2020005807A1 (en) * 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
WO2020005877A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CA3121408A1 (en) * 2018-11-30 2020-06-04 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
JP7470713B2 (ja) 2019-04-24 2024-04-18 ă‚»ăƒ©ăƒŽă‚Ąăƒłă‚č ăƒă‚€ă‚Șăƒ•ă‚ĄăƒŒăƒž ă‚ąăƒŒăƒ«ïŒ†ăƒ‡ă‚ŁăƒŒ ă‚ąă‚€ăƒ”ăƒŒïŒŒ ă‚šăƒ«ă‚šăƒ«ă‚·ăƒŒ ïŒȘïœïœ‹ă‚­ăƒŠăƒŒă‚Œé˜»ćźłć‰€ăšă—ăŠăźă‚šă‚čăƒ†ăƒ«ăŠă‚ˆăłă‚«ăƒ«ăƒœăƒŠăƒŒăƒˆăƒ”ăƒȘăƒŸă‚žăƒłćŒ–ćˆç‰©
PL3959213T3 (pl) 2019-04-24 2024-11-04 Theravance Biopharma R&D Ip, Llc Pirymidynowe inhibitory JAK w leczeniu chorĂłb skĂłry
KR20220042159A (ko) 2019-08-01 2022-04-04 읞테귞랄 ë°”ìŽì˜€ì‚ŹìŽì–žìŠ€ 플람읎티. 엘티디. 킀나제 ì–”ì œì œëĄœì„œì˜ í—€í…ŒëĄœì‚ŹìŽíŽëŠ­ í™”í•©ëŹŒ 및 읎의 용도
PL4031547T3 (pl) 2019-09-18 2024-10-07 Takeda Pharmaceutical Company Limited Inhibitory kalikreiny osoczowej i ich zastosowania
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
CN110483493A (zh) * 2019-09-19 2019-11-22 ćčżäžœć·„䞚性歊 侀种äșŒć”‘ç±»èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚
MX2022008627A (es) 2020-01-13 2022-11-08 Verge Analytics Inc Pirazolo-pirimidinas sustituidas y usos de las mismas.
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
TW202237119A (zh) 2020-12-10 2022-10-01 çŸŽć•†äœć‹èŁœè—„è…«ç˜€ć…Źćž ïŒĄïœŒïœ‹ïč˜ïŒ•æŠ‘ćˆ¶ćŠ‘ć’ŒćœŒäč‹ç”šé€”
EP4308564A1 (en) * 2021-03-17 2024-01-24 Takeda Pharmaceutical Company Limited Polycyclic inhibitors of plasma kallikrein
US20240197729A1 (en) * 2021-03-26 2024-06-20 Sumitomo Pharma Oncology, Inc. ALK-5 Inhibitors and Uses Thereof
WO2022240876A1 (en) 2021-05-11 2022-11-17 Oric Pharmaceuticals, Inc. Polo like kinase 4 inhibitors
TW202317574A (zh) 2021-06-28 2023-05-01 çŸŽć•†çșœćœ–è—„擁慬揾 ïŒŁïœ„ïœ‹ïŒ’æŠ‘ćˆ¶ćŠ‘
KR102692529B1 (ko) * 2021-07-01 2024-08-08 한ꔭ원자렄의학원 Mastl-pp2aë„Œ 표적화하는 암의 예방 또는 ìč˜ëŁŒìš© 앜학적 ìĄ°ì„±ëŹŒ
CN116354938B (zh) * 2021-12-28 2024-02-20 æČˆé˜łèŻç§‘ć€§ć­Š 䞀类ć–čć”‘ć•‰èĄç”Ÿç‰©äžŽć…¶ç±»äŒŒç‰©çš„ćˆ¶ć€‡æ–čæł•ćŠćș”甚
CN114276302B (zh) * 2022-01-11 2023-07-25 ć±±äžœç™ŸćŻç”Ÿç‰©ćŒ»èŻæœ‰é™ć…Źćž äž€ç§ćˆ¶ć€‡2,4-äșŒæ°šćŸșć–čć”‘ć•‰èĄç”Ÿç‰©çš„æ–čæł•
CN116813595B (zh) * 2022-03-28 2025-07-18 äžŠæ”·ćŒ»èŻć·„äžšç ”ç©¶é™ąæœ‰é™ć…Źćž ć–čć”‘ć•‰ç±»èĄç”Ÿç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ă€èŻç‰©ç»„ćˆç‰©ćŠćș”甚
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
CN115403568B (zh) * 2022-09-21 2023-09-29 䞭汱性歊 侀种ć–č攑敉类Aurora Ać…±ä»·æŠ‘ćˆ¶ć‰‚ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚
CN117736198A (zh) * 2022-09-21 2024-03-22 科蟉æ™șèŻç”Ÿç‰©ç§‘æŠ€(æ·±ćœł)æœ‰é™ć…Źćž ć€§çŽŻć«æ°źć† é†šćŒ–ćˆç‰©ćŠć…¶äœœäžșè›‹ç™œæż€é…¶æŠ‘ćˆ¶ć‰‚çš„ćș”甚
CN121001717A (zh) * 2023-02-23 2025-11-21 憰æŽČçŸłç”Ÿç‰©ç§‘æŠ€ć…Źćž 䜜äžșcdk2æŠ‘ćˆ¶ć‰‚çš„æ–°ćž‹ć€§çŽŻæ°šćŸșćĄć”‘ćŒ–ćˆç‰©
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133081A (en) 1964-05-12 J-aminoindazole derivatives
US18436A (en) * 1857-10-20 And saml
US2585906A (en) 1952-02-12 Quaternary salts of pyrimdjines
US3935183A (en) 1970-01-26 1976-01-27 Imperial Chemical Industries Limited Indazole-azo phenyl compounds
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US3998951A (en) 1974-03-13 1976-12-21 Fmc Corporation Substituted 2-arylquinazolines as fungicides
DE2458965C3 (de) 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsÀure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
MA18829A1 (fr) 1979-05-18 1980-12-31 Ciba Geigy Ag Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique
DOP1981004033A (es) * 1980-12-23 1990-12-29 Ciba Geigy Ag Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas.
SE8102193L (sv) 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och dess anvendning
SE8102194L (sv) 1981-04-06 1982-10-07 Pharmacia Ab Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
JPS58124773A (ja) 1982-01-20 1983-07-25 Mitsui Toatsu Chem Inc ïŒ•âˆ’ăƒĄăƒăƒ«ăƒă‚ȘピăƒȘミゾンèȘ˜ć°Žäœ“ăšăăźèŁœé€ æł•ăšèŸČćœ’èŠžç”šæźșèŒć‰€
EP0136976A3 (de) 1983-08-23 1985-05-15 Ciba-Geigy Ag Verwendung von Phenylpyrimidinen als Pflanzenregulatoren
DE3725638A1 (de) 1987-08-03 1989-02-16 Bayer Ag Neue aryloxy (bzw. thio)aminopyrimidine
JPH0532662A (ja) 1990-11-09 1993-02-09 Nissan Chem Ind Ltd çœźæ›ăƒ”ăƒ©ă‚ŸăƒŒăƒ«èȘ˜ć°Žäœ“ăŠă‚ˆăłèŸČćœ’èŠžç”šæźșèŒć‰€
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5597920A (en) 1992-04-30 1997-01-28 Neurogen Corporation Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes
JPH0665237A (ja) 1992-05-07 1994-03-08 Nissan Chem Ind Ltd çœźæ›ăƒ”ăƒ©ă‚ŸăƒŒăƒ«èȘ˜ć°Žäœ“ăŠă‚ˆăłèŸČćœ’èŠžç”šæźșèŒć‰€
ATE325113T1 (de) 1993-10-01 2006-06-15 Novartis Pharma Gmbh Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
JPH10509708A (ja) 1994-11-10 1998-09-22 コケ ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚čïŒŒă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ă‚Łăƒ‰ ăƒ—ăƒ­ăƒ†ă‚€ăƒłăƒ»ă‚­ăƒŠăƒŒă‚Œăźă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒăšă—ăŠæœ‰ç”šăȘćŒ»è–Źăƒ”ăƒ©ă‚ŸăƒŒăƒ«ç”„æˆç‰©
IL117659A (en) 1995-04-13 2000-12-06 Dainippon Pharmaceutical Co Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
WO1997009325A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
JPH10130150A (ja) 1996-09-05 1998-05-19 Dainippon Pharmaceut Co Ltd 酱酾ケミドèȘ˜ć°Žäœ“からăȘă‚‹ćŒ»è–Ź
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
JP4205168B2 (ja) 1996-10-02 2009-01-07 ăƒŽăƒăƒ«ăƒ†ă‚Łă‚č ケクチスンă‚Čă‚Œăƒ«ă‚·ăƒ€ăƒ•ăƒˆ ピăƒȘミゾンèȘ˜ć°Žäœ“ăŠă‚ˆăłăăźèŁœé€ æł•
WO1998016502A1 (en) 1996-10-11 1998-04-23 Warner-Lambert Company ASPARTATE ESTER INHIBITORS OF INTERLEUKIN-1ÎČ CONVERTING ENZYME
DE19710435A1 (de) * 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur PrĂ€vention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
EA200000409A1 (ru) 1997-10-10 2000-10-30 ĐĄĐ°ĐčŃ‚ĐŸĐČоэ, Đ˜ĐœĐș. ĐĄĐŸĐ”ĐŽĐžĐœĐ”ĐœĐžĐ”, Ń„Đ°Ń€ĐŒĐ°Ń†Đ”ĐČтОчДсĐșая ĐșĐŸĐŒĐżĐŸĐ·ĐžŃ†ĐžŃ, ŃĐżĐŸŃĐŸĐ± ĐžĐœĐłĐžĐ±ĐžŃ€ĐŸĐČĐ°ĐœĐžŃ гОбДлО ĐșлДтĐșĐž ĐČ ĐŸĐŽĐœĐŸĐč ĐșлДтĐșĐ” ОлО тĐșĐ°ĐœĐž, ŃĐżĐŸŃĐŸĐ± Đ»Đ”Ń‡Đ”ĐœĐžŃ ОлО ŃĐœĐžĐ¶Đ”ĐœĐžŃ ĐșĐ»Đ”Ń‚ĐŸŃ‡ĐœĐŸĐč ŃĐŒĐ”Ń€Ń‚Đž, ŃĐżĐŸŃĐŸĐ± Đ»Đ”Ń‡Đ”ĐœĐžŃ ОлО ĐżŃ€ĐŸŃ„ĐžĐ»Đ°ĐșтоĐșĐž ĐżĐŸĐ»ĐžĐșĐžŃŃ‚ĐŸĐ·ĐœĐŸĐłĐŸ Đ·Đ°Đ±ĐŸĐ»Đ”ĐČĐ°ĐœĐžŃ ĐżĐŸŃ‡Đ”Đș ОлО Đ°ĐœĐ”ĐŒĐžĐž/ŃŃ€ĐžŃ‚Ń€ĐŸĐżĐŸŃĐ·Đ° у жОĐČĐŸŃ‚ĐœŃ‹Ń…, ŃĐżĐŸŃĐŸĐ± защОты ĐŸŃ€ĐłĐ°ĐœĐ° ОлО тĐșĐ°ĐœĐž ĐŒĐ»Đ”ĐșĐŸĐżĐžŃ‚Đ°ŃŽŃ‰Đ”ĐłĐŸ ĐŸŃ‚ гОбДлО ĐșĐ»Đ”Ń‚ĐŸĐș, ŃĐżĐŸŃĐŸĐ± ŃĐœĐžĐ¶Đ”ĐœĐžŃ ОлО ĐżŃ€ĐŸŃ„ĐžĐ»Đ°ĐșтоĐșĐž гОбДлО ĐșĐ»Đ”Ń‚ĐŸĐș ĐČ ĐŸŃ€ĐłĐ°ĐœĐ” ОлО тĐșĐ°ĐœĐž ĐŽĐŸĐœĐŸŃ€Đ° ĐżĐŸŃĐ»Đ” ох Ń‚Ń€Đ°ĐœŃĐżĐ»Đ°ĐœŃ‚Đ°Ń†ĐžĐž, ŃĐżĐŸŃĐŸĐ± ŃĐœĐžĐ¶Đ”ĐœĐžŃ ОлО ĐżŃ€Đ”ĐŽĐŸŃ‚ĐČŃ€Đ°Ń‰Đ”ĐœĐžŃ гОбДлО ŃĐżĐ”Ń€ĐŒŃ‹ ОлО яĐčцДĐșĐ»Đ”Ń‚ĐŸĐș
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
JP2000026421A (ja) 1998-01-29 2000-01-25 Kumiai Chem Ind Co Ltd ゾケăƒȘâ€•ăƒ«ă‚čăƒ«ăƒ•ă‚Łăƒ‰èȘ˜ć°Žäœ“ćŠăłæœ‰ćźłç”Ÿç‰©é˜Č陀所
CA2321153A1 (en) 1998-02-17 1999-08-19 Timothy D. Cushing Anti-viral pyrimidine derivatives
KR20010041905A (ko) 1998-03-16 2001-05-25 시토ëč„ì•„ ìžíŹ. 디펩티드 ìčŽìŠ€íŒŒì œ 얔제제 및 읎의 용도
JP4611524B2 (ja) 1998-06-02 2011-01-12 ă‚ȘăƒŒă‚šă‚čă‚ąă‚€ăƒ»ăƒ•ă‚ĄăƒŒăƒžă‚čăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹăƒŒăƒ†ăƒƒăƒ‰ ăƒ”ăƒ­ăƒ­ïŒ»ïŒ’ïŒŒïŒ“ïœ„ïŒœăƒ”ăƒȘăƒŸă‚žăƒłç”„æˆç‰©ăŠă‚ˆăłăăźäœżç”š
JP4533534B2 (ja) 1998-06-19 2010-09-01 ăƒŽăƒăƒ«ăƒ†ă‚Łă‚č ăƒă‚Żă‚·ăƒłă‚ș ケンド ăƒ€ă‚€ă‚ąă‚°ăƒŽă‚čティックă‚čïŒŒă‚€ăƒłă‚łăƒŒăƒăƒŹăƒŒăƒ†ăƒƒăƒ‰ グăƒȘă‚łăƒŒă‚Čăƒłă‚·ăƒłă‚żăƒŒă‚Œă‚­ăƒŠăƒŒă‚ŒïŒ“ăźă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒ
WO2000003901A1 (de) * 1998-07-16 2000-01-27 Continental Teves Ag & Co. Ohg Verfahren und vorrichtung zum ermitteln von kritischen fahrzustÀnden bei im fahrbetrieb befindlichen fahrzeugen
WO2000011003A1 (en) 1998-08-21 2000-03-02 Du Pont Pharmaceuticals Company ISOXAZOLO[4,5-d]PYRIMIDINES AS CRF ANTAGONISTS
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
HK1039126B (en) * 1998-10-08 2005-09-30 é˜żæ–Żç‰čæ‹‰æ›Ÿć°ŒćĄæœ‰é™ć…Źćž Quinazoline derivatives
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
AP2001002225A0 (en) 1999-01-13 2001-09-30 Warner Lambert Co 1-heterocycle substituted diarylamines.
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
EP1165085B1 (en) 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
WO2000078757A1 (en) 1999-06-17 2000-12-28 Shionogi Bioresearch Corp. Inhibitors of il-12 production
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
CZ2002534A3 (cs) 1999-08-13 2002-07-17 Vertex Pharmaceuticals Incorporated Inhibitory protein-kinĂĄz, farmaceutickĂ© prostƙedky, kterĂ© je obsahujĂ­, a jejich pouÄŸitĂ­
ES2306671T3 (es) 1999-10-07 2008-11-16 Amgen Inc. Inhibidores de triazina quinasa.
TR200201431T2 (tr) 1999-11-30 2002-09-23 Pfizer Products Inc. Ä°mĂŒnosupresanlar olarak faydalı 2,4-diaminopirimidin bileƟikleri
DK1246623T3 (da) 1999-12-02 2006-11-13 Osi Pharm Inc Forbindelser, som er specifikke for adenosin A1-, A2a- og A3-receptor og anvendelser deraf
US6376489B1 (en) 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
MY125768A (en) 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
DE60043397D1 (de) 1999-12-28 2010-01-07 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
CZ20013540A3 (cs) 2000-02-05 2002-03-13 Vertex Pharmaceuticals Incorporated DerivĂĄty pyrazolu jako inhibitory ERK a farmaceutickĂœ prostƙedek, kterĂœ je obsahuje
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
ATE297946T1 (de) 2000-04-03 2005-07-15 Vertex Pharma Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease
CA2398446A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
JP3890184B2 (ja) * 2000-05-15 2007-03-07 ïŒźïœ…ïœƒăƒ‘ăƒŒă‚œăƒŠăƒ«ăƒ—ăƒ­ăƒ€ă‚Żăƒ„æ ȘćŒäŒšç€Ÿ 電æșèŁ…çœźćŠăłăăźé›»ćŠ›ćˆ¶ćŸĄæ–čæł•ă€æƒ…ć ±ć‡Šç†æ©Ÿć™š
IL153246A0 (en) 2000-06-28 2003-07-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
CN1498224A (zh) 2000-07-21 2004-05-19 ïżœïżœïżœéč«ËŸ ç”šäœœäž™ćž‹è‚ç‚Žç—…æŻ’ns3-äžæ°šé…žè›‹ç™œé…¶æŠ‘ćˆ¶ć‰‚çš„æ–°ćž‹è‚œ
CZ2003468A3 (cs) 2000-08-31 2004-05-12 PfizerĂĄproductsĂĄinc DerivĂĄty pyrazolu a jejich pouĆŸitĂ­ jako inhibitorĆŻ proteinkinĂĄzy
DE60122176T2 (de) 2000-09-15 2007-07-05 Vertex Pharmaceuticals Inc., Cambridge Isoxazole und ihre verwendung als erk-inhibitoren
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001296871A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2004509876A (ja) 2000-09-20 2004-04-02 ăƒĄăƒ«ă‚Żă€€ăƒ‘ăƒ†ăƒłăƒˆă€€ă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆă€€ăƒŸăƒƒăƒˆă€€ăƒ™ă‚·ăƒ„ăƒŹăƒłă‚Żăƒ†ăƒ«ă€€ăƒăƒ•ăƒˆăƒłă‚° ïŒ”âˆ’ă‚ąăƒŸăƒŽâˆ’ă‚­ăƒŠă‚ŸăƒȘン
US6641579B1 (en) * 2000-09-29 2003-11-04 Spectrasonics Imaging, Inc. Apparatus and method for ablating cardiac tissue
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
EP1351691A4 (en) 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
DE10061863A1 (de) 2000-12-12 2002-06-13 Basf Ag Verfahren zur Herstellung von Triethylendiamin (TEDA)
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
CA2441733A1 (en) 2001-03-29 2002-10-10 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
JP2004535381A (ja) 2001-04-13 2004-11-25 ăƒăƒŒăƒ†ăƒƒă‚Żă‚čă€€ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șă€€ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ −ïŒȘïœ•ïœŽïŒźæœ«ç«Żă‚­ăƒŠăƒŒă‚ŒïŒˆïŒȘïŒźïŒ«ïŒ‰ăŠă‚ˆăłä»–ăźăƒ—ăƒ­ăƒ†ă‚€ăƒłă‚­ăƒŠăƒŒă‚Œăźă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒ
US20030096813A1 (en) 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
AU2002308748A1 (en) 2001-05-16 2002-11-25 Vertex Pharmaceuticals Incorporated Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
EP1399440B1 (en) 2001-06-15 2009-06-03 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors
DE60214198T2 (de) 2001-07-03 2007-08-09 Vertex Pharmaceuticals Inc., Cambridge Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
WO2003026666A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
US6569499B2 (en) * 2001-10-02 2003-05-27 Xerox Corporation Apparatus and method for coating photoreceptor substrates
MXPA04005510A (es) 2001-12-07 2006-02-24 Vertex Pharma Compuestos basados en pirimidina utiles como inhibidores de gsk-3.
EP1485100B1 (en) 2002-03-15 2010-05-05 Vertex Pharmaceuticals Incorporated Azinylaminoazoles as inhibitors of protein kinases
WO2003078426A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazine as inhibitors of protein kinases
EP1485380B1 (en) 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines as inhibitors of protein kinases
ATE365733T1 (de) 2002-03-15 2007-07-15 Vertex Pharma Zusammensetzungen brauchbar als protein-kinase- inhibitoren
US20030207873A1 (en) 2002-04-10 2003-11-06 Edmund Harrington Inhibitors of Src and other protein kinases
WO2003091246A1 (en) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
PL374967A1 (en) 2002-08-02 2005-11-14 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of gsk-3
ES2535854T3 (es) 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
AU2007333650A1 (en) 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases

Also Published As

Publication number Publication date
KR100843114B1 (ko) 2008-07-02
IL156389A0 (en) 2004-01-04
MXPA03005612A (es) 2003-10-06
AP2003002825A0 (en) 2003-09-30
ATE326462T1 (de) 2006-06-15
AP1588A (en) 2006-03-06
AR040925A1 (es) 2005-04-27
DE60120219D1 (de) 2006-07-06
EP1345925B1 (en) 2006-05-17
ES2280313T3 (es) 2007-09-16
US6656939B2 (en) 2003-12-02
MXPA03005605A (es) 2003-10-06
EP1345927A1 (en) 2003-09-24
TWI290551B (en) 2007-12-01
EP1345926B1 (en) 2006-05-17
JP2013213068A (ja) 2013-10-17
JP2008247921A (ja) 2008-10-16
DE60123283T2 (de) 2007-04-12
US20030036543A1 (en) 2003-02-20
CA2432223C (en) 2008-05-20
US20030055068A1 (en) 2003-03-20
EP1353916B1 (en) 2006-09-20
EP1345926A2 (en) 2003-09-24
JP2004516292A (ja) 2004-06-03
EP1702920A1 (en) 2006-09-20
JP4160392B2 (ja) 2008-10-01
DE60123283D1 (de) 2006-11-02
US8697698B2 (en) 2014-04-15
ES2265450T3 (es) 2007-02-16
EP1345925A2 (en) 2003-09-24
ATE354573T1 (de) 2007-03-15
WO2002059111A3 (en) 2003-01-09
DK1345922T3 (da) 2006-09-18
IL156407A0 (en) 2004-01-04
DE60126658D1 (de) 2007-03-29
HK1060557A1 (en) 2004-08-13
IL156369A (en) 2011-02-28
MY140377A (en) 2009-12-31
EP1345922A1 (en) 2003-09-24
JP4210520B2 (ja) 2009-01-21
NO20032704D0 (no) 2003-06-13
CN100406454C (zh) 2008-07-30
CN1486310A (zh) 2004-03-31
WO2002050066A3 (en) 2003-01-23
CA2432303A1 (en) 2002-08-29
CA2432799A1 (en) 2002-06-27
AU2002255452B2 (en) 2006-06-08
NZ526475A (en) 2005-06-24
WO2002059112A3 (en) 2003-02-06
US20140187772A1 (en) 2014-07-03
JP2004519479A (ja) 2004-07-02
HK1062565A1 (zh) 2004-11-12
KR20030061465A (ko) 2003-07-18
NZ526470A (en) 2006-03-31
JP2004518703A (ja) 2004-06-24
CA2432131A1 (en) 2002-08-01
KR20030061466A (ko) 2003-07-18
NZ526469A (en) 2005-10-28
CA2432132A1 (en) 2002-08-01
JP4160389B2 (ja) 2008-10-01
CN1487933A (zh) 2004-04-07
EP1345927B1 (en) 2006-05-17
US20030004161A1 (en) 2003-01-02
SI1355905T1 (sl) 2007-08-31
US20050038023A1 (en) 2005-02-17
CA2432222C (en) 2008-07-29
DE60126828T2 (de) 2007-11-08
HUP0400908A2 (hu) 2004-07-28
JP2008201808A (ja) 2008-09-04
ES2375491T3 (es) 2012-03-01
DE60126828D1 (de) 2007-04-05
AR042397A1 (es) 2005-06-22
DE60120219T2 (de) 2007-04-12
JP5249842B2 (ja) 2013-07-31
KR20030061857A (ko) 2003-07-22
IL156408A0 (en) 2004-01-04
HUP0400641A3 (en) 2010-03-29
PT1345922E (pt) 2006-09-29
US7087603B2 (en) 2006-08-08
CA2432872A1 (en) 2002-06-27
ES2265452T3 (es) 2007-02-16
HK1060349A1 (en) 2004-08-06
ATE528303T1 (de) 2011-10-15
US20080287444A1 (en) 2008-11-20
NO20032736L (no) 2003-08-18
SI1353916T1 (sl) 2007-02-28
HUP0400842A2 (hu) 2004-07-28
AU2006201267B2 (en) 2010-07-29
CA2432872C (en) 2008-09-23
NO20032704L (no) 2003-08-21
EP1345928A2 (en) 2003-09-24
PL363244A1 (en) 2004-11-15
NZ526468A (en) 2004-03-26
JP2009155352A (ja) 2009-07-16
US20040132781A1 (en) 2004-07-08
PL210066B1 (pl) 2011-11-30
KR100947185B1 (ko) 2010-03-15
WO2002057259A3 (en) 2003-04-24
ES2265446T3 (es) 2007-02-16
EP1702920B1 (en) 2011-10-12
DE60119774T2 (de) 2007-05-16
WO2002059112A2 (en) 2002-08-01
DE60119777D1 (de) 2006-06-22
HK1062433A1 (en) 2004-11-05
NO20032703D0 (no) 2003-06-13
US6727251B2 (en) 2004-04-27
HK1060347A1 (en) 2004-08-06
KR100909665B1 (ko) 2009-07-29
DK1353916T3 (da) 2007-01-29
US20040214814A1 (en) 2004-10-28
IL209827A0 (en) 2011-02-28
US20030022885A1 (en) 2003-01-30
WO2002050065A3 (en) 2002-10-24
AU2006201267A1 (en) 2006-04-27
CA2432131C (en) 2008-07-08
EP2264028A1 (en) 2010-12-22
RU2355688C2 (ru) 2009-05-20
JP2008222719A (ja) 2008-09-25
CA2432223A1 (en) 2002-09-06
TW200716617A (en) 2007-05-01
US6653300B2 (en) 2003-11-25
DE60119776T2 (de) 2007-05-16
EP1353916A2 (en) 2003-10-22
ATE326463T1 (de) 2006-06-15
CN1549812A (zh) 2004-11-24
RU2003122209A (ru) 2005-02-10
DE60119774D1 (de) 2006-06-22
ATE326460T1 (de) 2006-06-15
PL210414B1 (pl) 2012-01-31
EP1345928B1 (en) 2007-02-14
NO328537B1 (no) 2010-03-15
DE60119775D1 (de) 2006-06-22
US6989385B2 (en) 2006-01-24
US7427681B2 (en) 2008-09-23
KR20030061858A (ko) 2003-07-22
JP2004517926A (ja) 2004-06-17
JP2004518743A (ja) 2004-06-24
MXPA03005609A (es) 2003-10-06
HUP0400639A2 (hu) 2004-06-28
KR20030061463A (ko) 2003-07-18
BR0116411A (pt) 2003-11-11
JP4160395B2 (ja) 2008-10-01
HUP0400908A3 (en) 2010-03-29
ATE353890T1 (de) 2007-03-15
AP2003002816A0 (en) 2003-06-30
JP2004517927A (ja) 2004-06-17
CA2432799C (en) 2008-08-19
US7982037B2 (en) 2011-07-19
IL156389A (en) 2011-01-31
JP2004516291A (ja) 2004-06-03
EP1355905A1 (en) 2003-10-29
HUP0400638A2 (hu) 2004-06-28
TWI313269B (en) 2009-08-11
NO20032670D0 (no) 2003-06-12
AU2002246754B2 (en) 2006-06-08
WO2002062789A1 (en) 2002-08-15
CY1106297T1 (el) 2011-10-12
JP2008189687A (ja) 2008-08-21
US20040157893A1 (en) 2004-08-12
NO20032736D0 (no) 2003-06-16
DK1355905T3 (da) 2007-06-18
US8304414B2 (en) 2012-11-06
ES2266095T3 (es) 2007-03-01
US20130096128A1 (en) 2013-04-18
IL156369A0 (en) 2004-01-04
PT1355905E (pt) 2007-05-31
JP4234435B2 (ja) 2009-03-04
NO20032671L (no) 2003-08-18
WO2002057259A2 (en) 2002-07-25
EP1345929A2 (en) 2003-09-24
CN102250071A (zh) 2011-11-23
KR100889246B1 (ko) 2009-03-19
JP2009286805A (ja) 2009-12-10
JP2008247920A (ja) 2008-10-16
BR0116493A (pt) 2003-09-30
MXPA03005606A (es) 2003-10-06
US20040167141A1 (en) 2004-08-26
EP1345922B1 (en) 2006-05-31
NO20032703L (no) 2003-08-19
PT1353916E (pt) 2007-01-31
EP1355905B1 (en) 2007-02-21
WO2002050066A2 (en) 2002-06-27
HUP0400639A3 (en) 2010-03-29
WO2002050065A2 (en) 2002-06-27
ATE340172T1 (de) 2006-10-15
US20030105090A1 (en) 2003-06-05
WO2002059111A2 (en) 2002-08-01
AU2001297619B2 (en) 2006-06-08
KR20030061468A (ko) 2003-07-18
US6653301B2 (en) 2003-11-25
MXPA03005607A (es) 2003-10-06
NZ526471A (en) 2005-08-26
CN100436452C (zh) 2008-11-26
NZ526472A (en) 2004-04-30
NO20032670L (no) 2003-08-15
CA2432132C (en) 2008-07-29
US7531536B2 (en) 2009-05-12
KR20030061464A (ko) 2003-07-18
EP1345929B1 (en) 2006-05-17
DE60119776D1 (de) 2006-06-22
NO20032671D0 (no) 2003-06-12
AU2002234047A1 (en) 2002-07-01
MXPA03005610A (es) 2003-10-06
US7625913B2 (en) 2009-12-01
CA2432222A1 (en) 2002-08-15
AU3116602A (en) 2002-07-01
AR042169A1 (es) 2005-06-15
AU2002231166B2 (en) 2008-02-21
NZ526473A (en) 2005-06-24
HK1059776A1 (en) 2004-07-16
DE60126658T2 (de) 2007-11-22
NO328501B1 (no) 2010-03-01
HUP0400641A2 (hu) 2004-06-28
ATE326461T1 (de) 2006-06-15
KR20030061467A (ko) 2003-07-18
KR100875091B1 (ko) 2008-12-22
CA2432129C (en) 2008-08-26
US20030078275A1 (en) 2003-04-24
CN100408573C (zh) 2008-08-06
JP2004517894A (ja) 2004-06-17
MXPA03005611A (es) 2003-10-06
ATE327989T1 (de) 2006-06-15
IL156368A0 (en) 2004-01-04
DE60119775T2 (de) 2007-05-10
CN100340555C (zh) 2007-10-03
CN1486311A (zh) 2004-03-31
WO2002066461A1 (en) 2002-08-29
WO2002068415A1 (en) 2002-09-06
US6664247B2 (en) 2003-12-16
US20030004164A1 (en) 2003-01-02
US20090312543A1 (en) 2009-12-17
ES2272567T3 (es) 2007-05-01
DE60119777T2 (de) 2007-05-03
JP2008260767A (ja) 2008-10-30
CA2432303C (en) 2010-04-13
MXPA03005608A (es) 2003-10-06
HK1061389A1 (en) 2004-09-17
JP2005097322A (ja) 2005-04-14
NO330527B1 (no) 2011-05-09
HK1060346A1 (en) 2004-08-06
CA2432129A1 (en) 2002-07-25
NZ526474A (en) 2005-10-28
JP2008189682A (ja) 2008-08-21
CN1486312A (zh) 2004-03-31
PL363246A1 (en) 2004-11-15

Similar Documents

Publication Publication Date Title
AR042398A1 (es) Compuestos de pirazol utiles como inhibidores de proteinquinasa
CA2422377A1 (en) Pyrazole compounds useful as protein kinase inhibitors
AR067762A1 (es) Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
AR044909A1 (es) Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
UY26143A1 (es) Derivados heterocĂ­clicos Ăștiles como agentes anticancerosos
ES2083773T3 (es) Derivados de 1,3-dihidro-2h-imidazo(4,5-b)quinolin-2-ona como inhibidores de fosfodiesterasa.
GT200000161A (es) Compuestos para el tratamiento de la isquemia.
PE20050013A1 (es) Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c
ES2095942T3 (es) Derivados de bencenoacetamida inhibidores del vih.
AR036248A1 (es) Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
MX9304151A (es) Nuevas ciclobut-3-en-1,2-dionas substituidas, proceso para su preparacion y composiciones farmaceuticas que las contienen.
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
MX2024012470A (es) Inhibidores de cinasas dependientes de ciclina 9 (cdk9)
DE60214401D1 (de) Hetero-bicyclische crf antagonisten
AR116036A1 (es) DERIVADOS DE NAFTIRIDINA COMO INHIBIDORES DE INTEGRINA avb6
AR016416A1 (es) Fenil-alquil-imidazoles, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de un medicamento
AR021968A1 (es) Oximas e hidrazonas sustituidas como antagonistas de neuroquinina
AR039008A1 (es) Derivados azabiciclicos, azatriciclicos y azaespirociclicos de aminociclohexano antagonistas de los receptores nmda, 5-ht3, y nicotinico neuronal
ES2057415T3 (es) Derivados biciclicos.
AR131141A1 (es) Inhibidores de eif4e y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure